Company news

COSCIENS Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015

August 6, 2015

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston

August 4, 2015

Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

July 29, 2015

Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology

July 28, 2015

Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® [Somatropin (rDNA origin) for Injection]

July 27, 2015

Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen(TM) in AGHD Meets EMA's Study-Design Expectations

May 26, 2015

Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting

May 11, 2015

Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results

May 7, 2015

Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.

May 7, 2015

Aeterna Zentaris to Announce First Quarter 2015 Financial and Operating Results on May 7, 2015 and Hold Annual & Special Shareholders Meeting on May 8, 2015

May 1, 2015

Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer

April 27, 2015

Aeterna Zentaris to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference in Toronto

April 23, 2015

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc.

April 23, 2015

Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin

April 16, 2015

Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen(TM) in AGHD Following Successful Meeting with FDA

April 13, 2015

Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina

March 31, 2015

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results

March 17, 2015

Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants

March 11, 2015

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015

March 10, 2015

Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants

March 6, 2015

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

March 5, 2015

Aeterna Zentaris to Present at Roth Conference 2015

March 2, 2015

Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco

January 6, 2015

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

December 29, 2014

Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

December 19, 2014

Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China

December 1, 2014

Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer

November 20, 2014

FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen(TM) NDA in Adult Growth Hormone Deficiency

November 6, 2014

Correction: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

November 5, 2014

Aeterna Zentaris Reports Third Quarter 2014 Financial and Operating Results

November 4, 2014

Aeterna Zentaris to Announce Third Quarter 2014 Financial and Operating Results on November 4, 2014

October 28, 2014

Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel®

October 27, 2014

Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and Corporate Secretary

October 7, 2014

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results

August 7, 2014

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston

August 6, 2014

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market

August 5, 2014

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014

July 31, 2014

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

June 11, 2014

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company

June 10, 2014

Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer

June 2, 2014

Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO

May 22, 2014

Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders

May 12, 2014

Aeterna Zentaris Announces At the Market Issuance Program

May 9, 2014

Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results

May 8, 2014

Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations

May 5, 2014

Aeterna Zentaris to Announce First Quarter 2014 Financial and Operating Results on May 8, 2014 and Hold Annual Shareholders Meeting on May 9, 2014

April 30, 2014

Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors

April 9, 2014

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

April 1, 2014

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs

March 28, 2014

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results

March 20, 2014

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.